Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies / M. Rondy, E. Kissling, H. Emborg, A. Gherasim, R. Pebody, R. Trebbien, F. Pozo, A. Larrauri, J. Mcmenamin, M. Valenciano, B. Kaic, S.K. Filipovic, V. Visekruna-Vucina, I.P. Novosel, Z. Lovric, G. Petrović, T.G. Krause, T.K. Fische, B. Lina, A. Falchi, A. Vilcu, C. Souty, T. Blanchon, S. van der Werf, V. Enouf, S. Behillil, M. Valette, S. Bernard-Stoecklin, D. Lévy-Bruhl, O. Launay, P. Loulergue, N. Lenzi, Z. Lesieur, A. L’Honneur, F. Galtier, C. Agostini, C. Serrand, C. Merle, V. Foulongne, P. Vanhems, F. Lainé, G. Lagathu, F. Carrat, S. Buda, U. Preuss, K. Prahm, B. Schweiger, M. Wedde, A. Heider, M. Martin, B. Biere, R. Duerrwald, L. Domegan, L. Coughlan, J. O’Donnell, M. Joyce, C. Collins, L. Dunford, J. Moran, G. Tuite, M. Duffy, J. Connell, C. de Gascun, C. Rizzo, A. Bella, V. Alfonsi, M.R. Castrucci, S. Puzelli, E. Pagani, V. Ghisetti, E. Pariani, F. Baldanti, G. Palù, P. D’Agaro, F. Ansaldi, P. Affanni, G.M. Rossolini, B. Camilloni, P. Bagnarelli, M. Sanguinetti, L. Atripaldi, M. Chironna, C. Serra, F. Vitale, M. Chironna, C. Germinario, A. Orsi, F. Ansaldi, I. Manini, E. Montomoli, C. Napoli, G.B. Orsi, I. Casado, J. Castilla, L. Fernandino, I. Martínez-Baz, G. Ezpeleta, A. Navascués, A. Pérez-García, A. Aguinaga, C. Ezpeleta, A. Meijer, S. van den Brink, W. van der Hoek, G. Goderski, L. Wijsman, M. Bagheri, F. Dijkstra, M. de Lange, T. Marzec, P. Overduin, A. Teirlinck, E. Wentink, G. Donker, S. Marbus, R. van Gageldonk-Lafeber, P. Schneeberger, J.J. van Oosterheert, V. Schweitzer, G. Groeneveld, B. Nunes, A. Machado, A.P. Rodrigues, V. Gomez, I. Kislaya, R. Guiomar, P. Pechirra, P. Cristóvão, I. Costa, A. Panarra, R. Côrte-Real, J. Poças, M.J. Peres, L.G. Comas, M.E.I. Marisquerena, J.C. Galán, M.D. Folgueira, F.G. Carril, R.S. Martínez, G. Cilla, J. Castilla, M.G. Cenoz, C.Q. Rubio, E.M. Ochoa, M. Blasco, J.G. Duran, J.M. Vanrell, J. Reina, D. Castrillejo, A.M. Gherasim, C. Delgado, J. Oliva, I. Casas, M. García, M. Latorre, A.M.M. Beamonte, A.M. Sapiña, M.O. Amores, A. Aizpurúa, M. Montes, K. Zakikhany, M. Brytting, Å. Wiman, A. Carnahan, F. Warburton, A. Djennad, J. Ellis, N. Andrews, D. Marques, S. Cottrell, A. Reynolds, R. Gunson, M. Galiano, A. Lackenby, C. Robertson, M. O’Doherty, M. Sinnathamby, I. Yonova, C. Moore, M. Sartaj, S. de Lusignan, M. Zambon, A. Moren, P. Penttinen. - In: EUROSURVEILLANCE. - ISSN 1025-496X. - 23:9(2018 Mar 01). [10.2807/1560-7917.ES.2018.23.9.18-00086]

Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies

E. Pariani;
2018

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Europe; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; epidemiology; public health, environmental and occupational health; virology
Settore MED/42 - Igiene Generale e Applicata
Article (author)
File in questo prodotto:
File Dimensione Formato  
eurosurv-23-9-1.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 532.52 kB
Formato Adobe PDF
532.52 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/582984
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 47
social impact